Early trials with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and with sodium-glucose cotransporter-2 inhibitors (SGLT2i) in persons with T2D and high CV risk were powered for CV outcomes as primary and kidney outcomes as secondary1,2. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.